VRN-07 is under clinical development by ORIC Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VRN-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VRN-07 overview

VRN-07 is under development for the treatment of solid tumors including non-small cell lung cancer and HER2 positive breast cancer. The therapeutic candidate is administered through oral route. The drug candidate development is based on voronoi kinase platform technology. The drug candidate act by targeting the epidermal growth factor receptor (EGFR) and HER2 with Exon 20 insertions.

ORIC Pharmaceuticals overview

ORIC Pharmaceuticals (ORIC) is a clinical-stage pharmaceutical company. It focuses on therapies to treat cancer. The company’s pipeline product pipeline includes ORIC-533, a orally bioavailable small molecule inhibitor for treatment of multiple myeloma; ORIC-114 to treat non-small cell lung cancer and breast and tumor agnostic; and ORIC-944 to treat prostate cancer. It is also developing multiple drug programs for therapeutic areas of breast cancer, and solid tumors. ORIC is headquartered in South San Francisco, California, the US.

For a complete picture of VRN-07’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.